Cabozantinib (BMS-907351)

For research use only.

Catalog No.S1119 Synonyms: XL184

94 publications

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.

Selleck's Cabozantinib (BMS-907351) has been cited by 94 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Targets
VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
Axl [1]
(Cell-free assay)
0.035 nM 1.3 nM 7 nM
In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E98NT  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kNE4xOS1zMDFOwG0> M2DZfWROW09? MXnJR|UxRTh7IH7N MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OESwNFYoRjJ|NEi0NFA3RC:jPh?=
SNU-5  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Gw[2lEPTB;IEG5JI5O M172U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
Hs746T  MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe0Xm16UUN3ME25Mlkhdk1? NWLZbXJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
SNU-1  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3uU25KSzVyPUWyNlMhdk1? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
SNU-16 M2O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPh[opkUUN3ME2xNVQ6KG6P MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
MDA-MB-231 NH:0V3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1iNkSyNUBvVQ>? MorlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
U87MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nxOGlEPTB;MUi1NUBvVQ>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
H441  NWjpRWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7FRW5bUUN3ME2yNVcxOCCwTR?= NF3wT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
H69 M{DoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL2fmNKSzVyPUKwNlAxKG6P M4XEO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
PC3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\FRYg4UUN3ME2xNFgxOCCwTR?= NYrQU4w5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
MTC-TT MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1yLkC0JEshOC5yMzFOwG0> M3LJTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
MZ-CRC Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\hNmlEPTB-IEWg{txO MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEm5OUc,OjF2N{C5PVU9N2F-
TPC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjoUlNMUUN3ME2wMlA3KCtiMD6wNkDPxE1? M1\YU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
NIH-3T3/TPR-Met NF7TTmpHfW6ldHnvckBie3OjeR?= MWfJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCrbjDtc5V{\SCQSVitN3Q{N1SSUj3N[ZQh[2WubIOsJGlEPTBiPTCxJO69VS5? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7NkG0OEc,OjR7OU[xOFQ9N2F-
BA/F3 MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFT0SJFKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDWSWdHWjJiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjygS2k2OCB;IECuNFA{KM7:TT6= M1rjVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BaF3 NEC3OGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fsWlQ5KGi{cx?= NYTmOVFsUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgVoV1KFN6OUHBJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCZWY{KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFEh|ryPLh?= M1Xpb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BA/F3 NG\LWVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnPsOFghcHK| MnXFTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViVFXMMYZ2e2WmIGLFWEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjB3IN88UU4> NVi1[llLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
TT MoruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXmxNEBl[Xm| NFH0N5FKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkAyOCCmYYnzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMUKg{txONg>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BA/F3 MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVq0PEBpenN? MnzQTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHY5ODSPIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLki5JO69VS5? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BaF3 MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXjlT3dKPDhiaILz M33Jd2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBXQDB2TDDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkmxJO69VS5? NYDDZoo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
Nthy-ori 3-1 MUXDfZRwfG:6aXPpeJkh[XO|YYm= M4TpflExKGSjeYO= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOeIh6NW:{aTCzMVEh[2WubIOgZYZ1\XJiMUCg[IF6eyCkeTDNWHQh[XO|YYmsJGdKPTBiPTC0Mlk{KM7:TT6= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3 MmGySpVv[3Srb36gZZN{[Xl? NV74OmJsOC5yMTD0c{AyOCC3TR?= MYGxJIhz M12zeGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIIfpcIQhfHmyZTDS[ZQhMHWwa37ve44hd3KrZ3nuLUBxcG:|cHjvdplt[XSrb36gZZQhYTFyNkKvXVkxPSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDheEAxNjBzIITvJFExKHWPIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT M2fl[mZ2dmO2aX;uJIF{e2G7 MWe0JIhzew>? NWHwS4lnUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUmwOUBqdiCqdX3hckBVXCClZXzsd{BifCBzIIXNJIFnfGW{IESgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M2HH[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BAF3 NVX2b3V6TnWwY4Tpc44h[XO|YYm= NXrxSJk2OC5yMTD0c{AyOCC3TR?= NYjIWY1jOSCqch?= NHfNXppKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdilicHjvd5Bpd3K7bHH0bY9vKGG2IGmxNFYzN1l7MEWg[ZhxemW|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XRiMD6wNUB1dyBzMDD1UUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NGHteJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BAF3 MlnqSpVv[3Srb36gZZN{[Xl? NYHXXWJxOC5yMTD0c{AyOCC3TR?= MXWxJIhz Mm\ETY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDQUGNo[W2vYTDheEB[Pzh|IHH0JFAvODFidH:gNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3 M17YfWZ2dmO2aX;uJIF{e2G7 MU[wMlAyKHSxIEGwJJVO MkjSNUBpeg>? NGPWSnZKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1cW:wIH;mJHNp[yCjdDDZN|E4KGG2IECuNFEhfG9iMUCgeW0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT NYn0V5hRTnWwY4Tpc44h[XO|YYm= NVrDTolSOSC2bzCxNEB2VQ>? NVLMc4k1PCCqcoO= NF7DVoZKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFzD[4FudWFicHjvd5Bpd3K7bHH0bY9vKGG2IGm3PFMh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT NWTjenA3TnWwY4Tpc44h[XO|YYm= MX2xJJRwKDFyIIXN MUO0JIhzew>? M{\GPGlvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxWUKwOEBifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NGHvNoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT MlPQSpVv[3Srb36gZZN{[Xl? NFXKSmcyKHSxIEGwJJVO MlyyOEBpenN? M{PFXmlvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JHQ{ODhxU{S3N{BifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT MmTSSpVv[3Srb36gZZN{[Xl? M4\DblEhfU1? NFzmTnRKdmirYnn0bY9vKG:oIGLleE1lemm4ZX6gc45kd2enbnnjJJRz[W6|Zn;ycYF1cW:wIH;mJIh2dWGwIGTUJINmdGy|IHH0JFEhfU1iYomgd49nfCCjZ3HyJIF{e2G7 MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT Mn\1SpVv[3Srb36gZZN{[Xl? NV35boVoOSC3TR?= M{\hdVQhcHK| NXLrNXloUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUGwOlIhcW5iaIXtZY4hXFRiY3XscJMh[XRiMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT NWK4T2dlSXCxcITvd4l{KGG|c3H5 NHHsTJIyKHWP MnfZPVYhcHK| MY\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFSWIHPlcIx{KGW6cILld5NqdmdiUnX0JGM3OzSZIH31eIFvfCCjdDCxJJVOKGGodHXyJFk3KGi{czDifUBidm6neHnuWk9RUSC|dHHpcolv\y2kYYPl[EBndG:5IHP5eI9u\XS{aXOgZY5idHm|aYO= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
PC3 M1nE[mZ2dmO2aX;uJIF{e2G7 NYXZfFBLOSC2bzCzJIhzew>? M3;YbGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEOyClZXzsd{BqdmO3YnH0[YQh\m:{IEGgeI8hOyCqcoOsJGlEPTBiPTCxMlkh|ryPLh?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
MDA-MB-231 NV7QU5NDTnWwY4Tpc44h[XO|YYm= NEKwb4syKHSxIEOgbJJ{ MnzITY5pcWKrdHnvckBw\iCDWFygdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKHSxIEOgbJJ{NCCLQ{WwJF0hPSEQvF2u NXP2OI5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3NVczODFpPkK2O|E4OjBzPD;hQi=>
BAF3 MVnGeY5kfGmxbjDhd5NigQ>? M2nIcVEhfG9iMzDodpM> NY\wPFBGUW6qaXLpeIlwdiCxZjDGUHQ{KCi3bnvuc5dvKG:{aXfpckkheGixc4Doc5J6dGG2aX;uJJRz[W6|ZnXjeIVlKGmwIH3veZNmKEKDRkOgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKHSxIEOgbJJ{NCCLQ{WwJF0hPy53IN88UU4> Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
MDA-MB-231 M3jXZWZ2dmO2aX;uJIF{e2G7 MYGxJJRwKDNiaILz MVfJcohq[mm2aX;uJI9nKEuLVDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSC2bzCzJIhzeyxiSVO1NEA:KDR{IN88UU4> Mnm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
BA/F3 MnLwSpVv[3Srb36gZZN{[Xl? MWi0PEBpenN? NIXNSZJKdmirYnn0bY9vKG:oIFvEVkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFPlcIwhfGm2cnWg[4xwNWKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4> MlTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O|QyRC:jPh?=
Sf21 NYLxTI1YTnWwY4Tpc44h[XO|YYm= MmGwNVUhdWmwcx?= MofyTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO|YYmsJGlEPTBiPTCwMlAyPiEQvF2u NVi3eYE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O|Q4PDFpPkK2PFc1PzRzPD;hQi=>
BA/F3 M3uwTWZ2dmO2aX;uJIF{e2G7 NYG4Z5d2PDhiaILz NX3vWGZRUW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlE6KM7:TT6= M1\2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O|QyLz5{Nki3OFc1OTxxYU6=
BA/F3 NV;YXm9ZTnWwY4Tpc44h[XO|YYm= NIrkNJY1QCCqcoO= NFzhSI5KdmirYnn0bY9vKG:oIFvJSlVDN1KHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEOnbHygeIl1emViZ3zvMYJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNVkh|ryPLh?= NHrEWFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O|Q4PDF:L3G+
BA/F3 NWD3dFBvSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2flUVczKGi{cx?= MlPRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJHRRWi2PZYSgZYZ1\XJiN{KgbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlAzOTlizszNMi=> NHTN[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2PFg5QSd-MkewOlg5QDl:L3G+
Sf21 NHO3NXRHfW6ldHnvckBie3OjeR?= MkWzOlAhdWmwcx?= M1TJNWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBz\WOxbXLpcoFvfCCqdX3hckBTTVRiKE[1PEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIHnud4VkfCCVZkKxJINmdGy|IIXzbY5oKHCxbImoS4x2NFS7cjm0PlEh[XNic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhPjBibXnud{BjgSCHTFnTRUwhUUN3MDC9JFAvODB|IN88UU4> M4fTXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Sf21 Mn7BSpVv[3Srb36gZZN{[Xl? NYfFUmZIPjBibXnudy=> NVztUlQyUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hWkWWIG[4NFROKG23dHHueEApPjV6IILld4llfWW|KTDlfJBz\XO|ZXSgbY4hcW6|ZXP0JHNnOjFiY3XscJMhfXOrbnegdI9tgSiJbIWsWJlzMTR8MTDhd{B{fWK|dILheIUhcW6ldXLheIVlKG[xcjC2NEBucW6|IHL5JGVNUVODLDDJR|UxKD1iMD64NVEh|ryPLh?= M2fmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
BaF3 NXvNeoU6TnWwY4Tpc44h[XO|YYm= MVK3NkBpenN? NFfTfJNKdmirYnn0bY9vKG:oIFPDSGM3NVKHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCZWY{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLki4PUDPxE1w MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MUC2Okc,OjdzM{GwOlY9N2F-
BaF3 NYfzTHV1TnWwY4Tpc44h[XO|YYm= M4H2blczKGi{cx?= M1HGdGlvcGmkaYTpc44hd2ZiQ1PER|YuWkWWIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwOEi5JO69VS5? NF:3bmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN|ExPjZ:L3G+
Ba/F3 MkSySpVv[3Srb36gZZN{[Xl? NY\pSVFMUW6qaXLpeIlwdiCxZjDSSXQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjB5IN88UU4> M1PRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
TT NHOyUmRHfW6ldHnvckBie3OjeR?= MknjTY5pcWKrdHnvckBw\iCURWSgR|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNlYh|ryPLh?= NUHKNG9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
Ba/F3 MVvGeY5kfGmxbjDhd5NigQ>? MWXJcohq[mm2aX;uJI9nKFKHVDDWPFA1VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjd2IN88UU4> NWnHZVhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
Nthy-ori 3-1 Mme3R5l1d3SxeHnjbZR6KGG|c3H5 NYH6UZFLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVnSqeT3vdokhOy1zIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IEKuPVIh|ryPLh?= NH3Md4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
HepG2 NWnCWZB3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NV7s[W1sPzJiaILz NX:1NGhQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xOTJizszNMi=> NVrkR45YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
EBC1 MnywRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHe3[|M4OiCqcoO= NUnHOldvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA2OTRizszNMi=> NYPTPZpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
H1299 MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHEVoc4OiCqcoO= NWH3cWZiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUDF{OUmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDFwOUG5JO69VS5? MlzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O|koRjJ6NkWxPVc6RC:jPh?=
MCF7 MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLxO|IhcHK| M3;HTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFIvQDh7IN88UU4> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
A549 MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmq1O|IhcHK| NW\oXW46T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC5{MEWg{txONg>? M3LVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D NFHDOWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkPxO|IhcHK| MoHLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFQ4TCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gOE41PDhizszNMi=> MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O|koRjJ6NkWxPVc6RC:jPh?=
H460 NYTEd2kxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlHVO|IhcHK| M2nXTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGg1PjBiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFUvPjZ7IN88UU4> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
HuH7 M17qTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NF3BZo41QCCqcoO= MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{S4JO69VS5? NF30dWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O|A1Oid-MkmwOVcxPDJ:L3G+
A498 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mmn6OFghcHK| NEL1ZlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEiuOFU3KM7:TT6= NEXYT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O|A1Oid-MkmwOVcxPDJ:L3G+
NCI-H727 M1n3cmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUS0PEBpenN? NHmwO3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPzJ5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyPC5yMTFOwG0v M2PGPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEW3NFQzLz5{OUC1O|A1OjxxYU6=
BAF3 MnLwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mn7jO|IhcHK| M33NT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegWHJRNU2HVDDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO|YYmsJGlEPTBiPTCwMlAzPCEQvF2u NW\jblJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFY1PTJpPkK5NVQ3PDV{PD;hQi=>
A549 MUHDfZRwfG:6aXPpeJkh[XO|YYm= NVH3W3hnOTBidV2= NYDJOnhHPzJiaILz Ml30R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BifCBzMDD1UUBi\nSncjC3NkBpenNiYomgTY5kfWO7dHWgcIl3\S2lZXzsJIlu[WerbnegZY5idHm|aYO= NEjFNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k3Oyd-Mkm0NFc6PjN:L3G+
A673 M1raVJFJXFNiYYPzZZk> NUjyb5U4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NXrwV4pmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY M1y1Z5FJXFNiYYPzZZk> NXnNVVg4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= NXjLTmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MX;xTHRUKGG|c3H5 NHjvVnhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz M{fNN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 M{OxNZFJXFNiYYPzZZk> NH62bW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MnO4dWhVWyCjc4PhfS=> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M4SxWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NGi5bVdyUFSVIHHzd4F6 MkXBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NH7KN5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 M1naVZFJXFNiYYPzZZk> Mmq4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NH\Pcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MoLldWhVWyCjc4PhfS=> MnvpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NH74Rpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NEXpRmNyUFSVIHHzd4F6 MmDndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M2faZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NU\CPW91eUiWUzDhd5NigQ>? NV6xdXZveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MlPEdWhVWyCjc4PhfS=> MnrsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> M4ntOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS NXXGeoVNeUiWUzDhd5NigQ>? MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM> NXftOFNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MYTxTHRUKGG|c3H5 MojCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{ NHPn[Jg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NEXwUmFyUFSVIHHzd4F6 MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NX\zbpd4eUiWUzDhd5NigQ>? MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NXmwfWNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MVHxTHRUKGG|c3H5 NViyZ21xeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NVnKXmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NYS2bpJmeUiWUzDhd5NigQ>? NU\BUlh3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NHzTSnpyUFSVIHHzd4F6 MkDDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NXrjRmgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NGfjRmZyUFSVIHHzd4F6 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 Mon6dWhVWyCjc4PhfS=> NYjaU2t3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= Ml;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 MmHQdWhVWyCjc4PhfS=> Mn76dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> M13pVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NIj6SY1yUFSVIHHzd4F6 MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
EBC1 NIfsUI9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NEnaTo84OiCqcoO= M3v2WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wNFQ5KM7:TT6= MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
MKN45 MkDSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MkH6O|IhcHK| NF[1b3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlAxPjlizszNMi=> M4rI[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5|MEK0PFY2PDxxYU6=
SNU5 MkLXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYC3NkBpenN? NHPo[XZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPOWVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFEzOSEQvF2u NELv[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
BAF3 NUnZTXI{TnWwY4Tpc44h[XO|YYm= Mlv5O|IhcHK| NEPKdIVKdmirYnn0bY9vKG:oIGTQVk11[WepZXSgcYV1KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEG5PFYh|ryPLh?= MmP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
NCI-H460 MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVLtWYZzPzJiaILz MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA1ODFizszNMi=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OE[1OEc,OzB{NEi2OVQ9N2F-
MGHU3 NUm1dlRjSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NY\VWJI1PzJiaILz NFvheoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HTHU{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5 M1PBdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{C5OlcyLz5|MEOwPVY4OTxxYU6=
RT112 Mn\vRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MkW4O|IhcHK| NUfNUmlHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSWFEyOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfS=> M4TNOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{C5OlcyLz5|MEOwPVY4OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; 

PubMed: 29188469     


MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM.

p-MET / p-ERK / p-AKT; 

PubMed: 29520051     


Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.

29188469 29520051
Immunofluorescence
α-tubulin; 

PubMed: 29520051     


Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.

29520051
Growth inhibition assay
Cell viability; 

PubMed: 23661005     


Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.

23661005
In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol

Cell Research:

[2]

- Collapse
  • Cell lines: ST88-14, STS26T, and MPNST724
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 48 hours
  • Method:

    Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 501.51
Formula

C28H24FN3O5

CAS No. 849217-68-1
Storage powder
in solvent
Synonyms XL184
Smiles COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04957160 Not yet recruiting -- Advanced Renal Cell Carcinoma (aRCC) Ipsen September 4 2021 --
NCT04868773 Recruiting Drug: Cabozantinib|Drug: TAS-102 Colorectal Cancer|Colorectal Carcinoma|Metastatic Cancer|CRC University of California Irvine July 2021 Phase 1
NCT04893785 Not yet recruiting Drug: Cabozantinib and Temozolomide Lung Neuroendocrine Neoplasm|GEP Neuroendocrine Tumor National Cancer Institute Naples June 2021 Phase 2
NCT04804813 Recruiting Drug: Cabozantinib Renal Cell Carcinoma Takeda March 29 2021 --
NCT04631744 Recruiting Drug: Cabozantinib Prostate Cancer Weill Medical College of Cornell University|Exelixis March 3 2021 Phase 2
NCT04300140 Recruiting Drug: AVB-S6-500|Drug: Cabozantinib (Cabo) Clear Cell Renal Cell Carcinoma Aravive Inc. February 26 2021 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) supplier | purchase Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) cost | Cabozantinib (BMS-907351) manufacturer | order Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID